| 000 | 01905 a2200565 4500 | ||
|---|---|---|---|
| 005 | 20250517114114.0 | ||
| 264 | 0 | _c20170608 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1537-6613 | ||
| 024 | 7 |
_a10.1093/infdis/jiw412 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHöner Zu Siederdissen, Christoph | |
| 245 | 0 | 0 |
_aViral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. _h[electronic resource] |
| 260 |
_bThe Journal of infectious diseases _c11 2016 |
||
| 300 |
_a1492-1497 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntiviral Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aCytokines _xblood |
| 650 | 0 | 4 |
_aDNA, Viral _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHepatitis B Core Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B e Antigens _xblood |
| 650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNucleosides _xadministration & dosage |
| 650 | 0 | 4 |
_aNucleotides _xadministration & dosage |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aWithholding Treatment |
| 700 | 1 | _aRinker, Franziska | |
| 700 | 1 | _aMaasoumy, Benjamin | |
| 700 | 1 | _aWiegand, Steffen B | |
| 700 | 1 | _aFilmann, Natalie | |
| 700 | 1 | _aFalk, Christine S | |
| 700 | 1 | _aDeterding, Katja | |
| 700 | 1 | _aPort, Kerstin | |
| 700 | 1 | _aMix, Carola | |
| 700 | 1 | _aManns, Michael P | |
| 700 | 1 | _aHerrmann, Eva | |
| 700 | 1 | _aWedemeyer, Heiner | |
| 700 | 1 | _aKraft, Anke R M | |
| 700 | 1 | _aCornberg, Markus | |
| 773 | 0 |
_tThe Journal of infectious diseases _gvol. 214 _gno. 10 _gp. 1492-1497 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/infdis/jiw412 _zAvailable from publisher's website |
| 999 |
_c26402717 _d26402717 |
||